Home › Compare › BCDAW vs JEPQ

BCDAW vs JEPQ: Dividend Comparison 2026

BCDAW yields 32786.89% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BCDAW wins by $7.149378406802545e+21M in total portfolio value
10 years
BCDAW
BCDAW
● Live price
32786.89%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.149378406802545e+21M
Annual income
$7,106,739,309,572,423,000,000,000,000.00
Full BCDAW calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — BCDAW vs JEPQ

📍 BCDAW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBCDAWJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BCDAW + JEPQ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BCDAW pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BCDAW
Annual income on $10K today (after 15% tax)
$2,786,885.25/yr
After 10yr DRIP, annual income (after tax)
$6,040,728,413,136,559,000,000,000,000.00/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, BCDAW beats the other by $6,040,728,413,136,559,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BCDAW + JEPQ for your $10,000?

BCDAW: 50%JEPQ: 50%
100% JEPQ50/50100% BCDAW
Portfolio after 10yr
$3.5746892034012726e+21M
Annual income
$3,553,369,654,786,211,600,000,000,000.00/yr
Blended yield
99.40%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BCDAW buys
0
JEPQ buys
0
No recent congressional trades found for BCDAW or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBCDAWJEPQ
Forward yield32786.89% ✓11.10%
Annual dividend / share$2.00$6.16 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$7.149378406802545e+21M$44.8K ✓
Annual income after 10y$7,106,739,309,572,423,000,000,000,000.00 ✓$2,152.59
Total dividends collected$7.146574325368343e+21M$16.3K ✓
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: BCDAW vs JEPQ ($10,000, DRIP)

YearBCDAW PortfolioBCDAW Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$3,289,389$3,278,688.52$11,930$1,110.39+$3.28M → BCDAW
2$1,011,452,394$1,007,932,748.46$14,133$1,224.34+$1011.44M → BCDAW
3$290,735,268,121$289,653,014,059.08$16,632$1,340.46+$290735.25M → BCDAW
4$78,123,080,869,461$77,811,994,132,571.95$19,454$1,457.97+$78123080.85M → BCDAW
5$19,624,484,924,633,140$19,540,893,228,102,816.00$22,626$1,576.08+$19624484924.61M → BCDAW
6$4,608,534,766,328,053,000$4,587,536,567,458,695,700.00$26,175$1,694.09+$4608534766328.03M → BCDAW
7$1,011,770,904,242,838,300,000$1,006,839,772,042,867,400,000.00$30,133$1,811.32+$1011770904242838.25M → BCDAW
8$207,666,224,199,856,750,000,000$206,583,629,332,316,930,000,000.00$34,531$1,927.17+$207666224199856768.00M → BCDAW
9$39,849,623,579,553,230,000,000,000$39,627,420,719,659,375,000,000,000.00$39,403$2,041.08+$39849623579553226752.00M → BCDAW
10$7,149,378,406,802,546,000,000,000,000$7,106,739,309,572,423,000,000,000,000.00$44,787$2,152.59+$7.149378406802545e+21M → BCDAW

BCDAW vs JEPQ: Complete Analysis 2026

BCDAW — Stock

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Full BCDAW Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this BCDAW vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BCDAW vs SCHDBCDAW vs JEPIBCDAW vs OBCDAW vs KOBCDAW vs MAINBCDAW vs XYLDBCDAW vs QYLDBCDAW vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.